RAPT Therapeutics’ (RAPT) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of RAPT Therapeutics (NASDAQ:RAPT) in a report issued on Tuesday morning,Benzinga reports.

Several other research analysts have also issued reports on the stock. Piper Sandler lowered shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $8.00 to $2.00 in a research note on Monday. JPMorgan Chase & Co. cut shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday. Finally, UBS Group dropped their target price on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a research report on Monday, September 9th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $13.00.

RAPT Therapeutics Trading Down 0.0 %

NASDAQ:RAPT opened at $1.28 on Tuesday. RAPT Therapeutics has a 1 year low of $1.25 and a 1 year high of $27.35. The firm has a 50 day moving average of $1.96 and a 200-day moving average of $3.05.

Institutional Investors Weigh In On RAPT Therapeutics

Several large investors have recently added to or reduced their stakes in RAPT. Hennion & Walsh Asset Management Inc. grew its holdings in RAPT Therapeutics by 8.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock worth $148,000 after purchasing an additional 3,824 shares during the period. Acadian Asset Management LLC bought a new stake in shares of RAPT Therapeutics during the first quarter valued at approximately $97,000. EntryPoint Capital LLC bought a new stake in shares of RAPT Therapeutics during the first quarter valued at approximately $161,000. Bank of New York Mellon Corp lifted its holdings in shares of RAPT Therapeutics by 24.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,590 shares of the company’s stock worth $349,000 after purchasing an additional 22,175 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its position in RAPT Therapeutics by 66.2% in the 2nd quarter. Los Angeles Capital Management LLC now owns 84,586 shares of the company’s stock valued at $258,000 after purchasing an additional 33,692 shares during the period. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.